{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:26Z","timestamp":1791245186168,"version":"4.1.0"},"reference-count":297,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["GR 2017-0800"],"award-info":[{"award-number":["GR 2017-0800"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente - IRCCS MultiMedica"],"award-info":[{"award-number":["Ricerca Corrente - IRCCS MultiMedica"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Chemotherapy and targeted therapies have significantly improved the prognosis of oncology patients. However, these antineoplastic treatments may also induce adverse cardiovascular effects, which may lead to acute or delayed onset of cardiac dysfunction. These common cardiovascular complications, commonly referred to as cardiotoxicity, not only may require the modification, suspension, or withdrawal of life-saving antineoplastic therapies, with the risk of reducing their efficacy, but can also strongly impact the quality of life and overall survival, regardless of the oncological prognosis. The onset of cardiotoxicity may depend on the class, dose, route, and duration of administration of anticancer drugs, as well as on individual risk factors. Importantly, the cardiotoxic side effects may be reversible, if cardiac function is restored upon discontinuation of the therapy, or irreversible, characterized by injury and loss of cardiac muscle cells. Subclinical myocardial dysfunction induced by anticancer therapies may also subsequently evolve in symptomatic congestive heart failure. Hence, there is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages. In this review, we summarize the knowledge regarding the cellular and molecular mechanisms contributing to the onset of cardiotoxicity associated with common classes of chemotherapy and targeted therapy drugs. Furthermore, we describe and discuss current and potential strategies to cope with the cardiotoxic side effects as well as cardioprotective preventive approaches that may be useful to flank anticancer therapies.<\/jats:p>","DOI":"10.3389\/fcvm.2022.847012","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T02:06:48Z","timestamp":1649988408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":175,"title":["Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection"],"prefix":"10.3389","volume":"9","author":[{"given":"Marco Bruno","family":"Morelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Da Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"D\u2019Uva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"B1","article-title":"Controversies in the definition of cardiotoxicity: do we care? \u2013 American college of cardiology.","author":"Lambert","year":"2016","journal-title":"Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines.","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000455823","article-title":"Primary prevention strategies for anthracycline cardiotoxicity: a brief overview.","volume":"62","author":"Menna","year":"2017","journal-title":"Chemotherapy."},{"key":"B4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs.","volume":"22","author":"Mercurio","year":"2016","journal-title":"J Card Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","article-title":"Anthracycline cardiotoxicity.","author":"Menna","year":"2012","journal-title":"Expert Opin Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMCIBR1214975","article-title":"Anthracyclines and heart failure.","volume":"368","author":"Sawyer","year":"2013","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience.","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging.","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Hear J Cardiovasc Imaging."},{"key":"B10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ejhf.457","article-title":"Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?","volume":"18","author":"Vaduganathan","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management.","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies.","volume":"113","author":"Ky","year":"2013","journal-title":"Circ Res."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00025","article-title":"The role of iron in anthracycline cardiotoxicity.","volume":"5","author":"Gammella","year":"2014","journal-title":"Front Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.","volume":"3","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/138148","article-title":"Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs.","volume":"2015","author":"Molinaro","year":"2015","journal-title":"Biomed Res Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure.","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/echo.13245","article-title":"Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia-a velocity vector imaging analysis.","volume":"33","author":"Shaikh","year":"2016","journal-title":"Echocardiography."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0305-7372(87)90021-1","article-title":"Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.","volume":"14","author":"Saletan","year":"1987","journal-title":"Cancer Treat Rev."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity.","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/cpt.614","article-title":"Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction.","volume":"101","author":"Tromp","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0696-8","article-title":"Pharmacogenetics of chemotherapy-induced cardiotoxicity.","volume":"20","author":"Chang","year":"2018","journal-title":"Curr Oncol Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1158\/0008-5472.CAN-06-4431","article-title":"Mapping genes that contribute to daunorubicin-induced cytotoxicity.","volume":"67","author":"Duan","year":"2007","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the children\u2019s oncology group.","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1042\/CBI20110264","article-title":"ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia.","volume":"36","author":"Semsei","year":"2012","journal-title":"Cell Biol Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/pgs.15.61","article-title":"Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.","volume":"16","author":"Visscher","year":"2015","journal-title":"Pharmacogenomics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood-2003-03-0869","article-title":"Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin.","volume":"102","author":"Miranda","year":"2003","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.651269","article-title":"Potential gene association studies of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis.","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation."},{"key":"B34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy \u2013 an update.","volume":"818","author":"Renu","year":"2018","journal-title":"Eur J Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy.","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ Res."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview.","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid Redox Signal."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.bbamcr.2016.01.021","article-title":"New signal transduction paradigms in anthracycline-induced cardiotoxicity.","volume":"1863","author":"Ghigo","year":"2016","journal-title":"Biochim Biophys Acta."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1111\/bph.12975","article-title":"Redox signalling and cardioprotection: translatability and mechanism.","volume":"172","author":"Pagliaro","year":"2015","journal-title":"Br J Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41569-018-0074-0","article-title":"Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.","volume":"16","author":"Bonora","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Expert consensus document: mitochondrial function as a therapeutic target in heart failure.","volume":"14","author":"Brown","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/RES.0000000000000104","article-title":"Mitochondrial function, biology, and role in disease: a scientific statement from the american heart association.","volume":"118","author":"Murphy","year":"2016","journal-title":"Circ Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/wsbm.1188","article-title":"Mitochondrial network energetics in the heart.","volume":"4","author":"Aon","year":"2012","journal-title":"Wiley Interdiscip Rev Syst Biol Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity.","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/s0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.","volume":"261","author":"Davies","year":"1986","journal-title":"J Biol Chem."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-013-0392-7","article-title":"Redox balance and cardioprotection.","volume":"108","author":"Tullio","year":"2013","journal-title":"Basic Res Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.bbabio.2009.02.008","article-title":"Cardioprotection: a radical view free radicals in pre and postconditioning.","volume":"1787","author":"Penna","year":"2009","journal-title":"Biochim Biophys Acta."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity.","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1039\/d1tb00551k","article-title":"The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery.","volume":"9","author":"Qin","year":"2021","journal-title":"J Mater Chem B."},{"key":"B51","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1124\/mol.63.4.849","article-title":"Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.","volume":"63","author":"Kwok","year":"2003","journal-title":"Mol Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132747","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.","volume":"5","author":"Tadokoro","year":"2020","journal-title":"JCI insight."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.freeradbiomed.2009.03.004","article-title":"Cytochrome c\/cardiolipin relations in mitochondria: a kiss of death.","volume":"46","author":"Kagan","year":"2009","journal-title":"Free Radic Biol Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/s0005-2736(01)00371-6","article-title":"Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers.","volume":"1514","author":"Parker","year":"2001","journal-title":"Biochim Biophys Acta."},{"key":"B55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.4017","article-title":"CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.","volume":"22","author":"Zhang","year":"2016","journal-title":"Nat Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-019-0182-6","article-title":"Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity.","volume":"5","author":"McSweeney","year":"2019","journal-title":"Cell Death Discov."},{"key":"B58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer.","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"16202","DOI":"10.1074\/jbc.275.21.16202","article-title":"Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling.","volume":"275","author":"Marchenko","year":"2000","journal-title":"J Biol Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nature03317","article-title":"Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death.","volume":"434","author":"Nakagawa","year":"2005","journal-title":"Nature."},{"key":"B61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrm3401","article-title":"Cell death: multitasking p53 promotes necrosis.","volume":"13","author":"Baumann","year":"2012","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.cell.2012.05.014","article-title":"p53 opens the mitochondrial permeability transition pore to trigger necrosis.","volume":"149","author":"Vaseva","year":"2012","journal-title":"Cell."},{"key":"B63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcdb.2019.05.011","article-title":"Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.","volume":"98","author":"Blandino","year":"2020","journal-title":"Semin Cell Dev Biol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00108","article-title":"Inhibition of mitochondrial p53 accumulation by PFT-\u03bc prevents cisplatin-induced peripheral neuropathy.","volume":"10","author":"Maj","year":"2017","journal-title":"Front Mol Neurosci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"19626","DOI":"10.1073\/pnas.1904979116","article-title":"p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.","volume":"116","author":"Li","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2020.1724598","article-title":"Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease.","volume":"7","author":"Nishi","year":"2020","journal-title":"Mol Cell Oncol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1089359","article-title":"Cardiac nonmyocyte cell functions and crosstalks in response to cardiotoxic drugs.","volume":"2017","author":"Gambardella","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management.","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines.","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr Treat Options Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.5306\/wjco.v11.i12.1008","article-title":"Fluoropyrimidine-induced cardiotoxicity.","volume":"11","author":"Deac","year":"2020","journal-title":"World J Clin Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity.","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/cj.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature.","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited.","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/187152506775268785","article-title":"Cardiotoxicity of 5-fluorouracil.","volume":"4","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.","author":"Madeddu","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"B76","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments.","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes.","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One."},{"key":"B78","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/molecules14010053","article-title":"Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia.","volume":"14","author":"Spasojevi\u0107","year":"2008","journal-title":"Molecules."},{"key":"B80","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: a review of adverse toxicities and novel delivery strategies.","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin Drug Saf."},{"key":"B81","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000471759","article-title":"Prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction.","volume":"12","author":"Osman","year":"2017","journal-title":"Breast Care (Basel)."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol.","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J Clin Oncol."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001849","article-title":"Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience.","volume":"8","author":"Batra","year":"2021","journal-title":"Open Hear."},{"key":"B84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3238\/arztebl.2014.0161","article-title":"Cardiotoxicity and oncological treatments.","volume":"111","author":"Schlitt","year":"2014","journal-title":"Dtsch Arztebl Int."},{"key":"B85","first-page":"117","article-title":"A reassessment of cardiac toxicity associated with taxol.","author":"Arbuck","year":"1993","journal-title":"J Natl Cancer Inst Monogr."},{"key":"B86","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/eci.12589","article-title":"Update on cardiotoxicity of anti-cancer treatments.","volume":"46","author":"Rosa","year":"2016","journal-title":"Eur J Clin Invest."},{"key":"B87","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs.","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat Rev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/CAD.0b013e3283394624","article-title":"Anticancer therapy induced cardiotoxicity: review of the literature.","volume":"21","author":"Geiger","year":"2010","journal-title":"Anticancer Drugs."},{"key":"B89","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1177\/10600280940280S507","article-title":"Patient care issues: the management of paclitaxel-related toxicities.","volume":"28","author":"Finley","year":"1994","journal-title":"Ann Pharmacother."},{"key":"B90","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (taxol).","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/s0891-5849(01)00616-5","article-title":"Direct effect of taxol on free radical formation and mitochondrial permeability transition.","volume":"31","author":"Varbiro","year":"2001","journal-title":"Free Radic Biol Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1200\/JCO.1997.15.5.1906","article-title":"Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.","volume":"15","author":"Gianni","year":"1997","journal-title":"J Clin Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jbt.20012","article-title":"Cardiotoxicity of doxorubicin\/paclitaxel combination in rats: effect of sequence and timing of administration.","volume":"18","author":"Saad","year":"2004","journal-title":"J Biochem Mol Toxicol."},{"key":"B94","first-page":"14","article-title":"Doxorubicin\/taxane combinations: cardiac toxicity and pharmacokinetics.","volume":"26","author":"Sparano","year":"1999","journal-title":"Semin Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action.","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms.","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.phrs.2005.12.005","article-title":"Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model.","volume":"53","author":"Al-Majed","year":"2006","journal-title":"Pharmacol Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies.","volume":"650","author":"El-Awady","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cbi.2013.11.008","article-title":"Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor, in cisplatin-induced cardiotoxicity in rats.","volume":"207","author":"El-Sawalhi","year":"2014","journal-title":"Chem Biol Interact."},{"key":"B102","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/biof.1301","article-title":"Taurine protects cisplatin induced cardiotoxicity by modulating inflammatory and endoplasmic reticulum stress responses.","volume":"42","author":"Chowdhury","year":"2016","journal-title":"Biofactors."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.","volume":"9","author":"Braverman","year":"1991","journal-title":"J Clin Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell."},{"key":"B105","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology.","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases.","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell."},{"key":"B107","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level.","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor.","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol Cell Biol."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer.","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct Target Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","article-title":"Neuregulin in cardiovascular development and disease.","volume":"111","author":"Odiete","year":"2012","journal-title":"Circ Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.yjmcc.2008.02.278","article-title":"ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.","volume":"44","author":"Fuller","year":"2008","journal-title":"J Mol Cell Cardiol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-018-0110-6","article-title":"Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation.","volume":"557","author":"Del Monte-Nieto","year":"2018","journal-title":"Nature."},{"key":"B114","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/CIRCRESAHA.110.218693","article-title":"Neuregulin 1 sustains the gene regulatory network in both trabecular and nontrabecular myocardium.","volume":"107","author":"Lai","year":"2010","journal-title":"Circ Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1242\/dev.053736","article-title":"A dual role for ErbB2 signaling in cardiac trabeculation.","volume":"137","author":"Liu","year":"2010","journal-title":"Development."},{"key":"B116","doi-asserted-by":"publisher","first-page":"H2139","DOI":"10.1152\/ajpheart.00063.2012ajpheart.00063.2012","article-title":"The role of neuregulin\/ErbB2\/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.","volume":"302","author":"Wadugu","year":"2012","journal-title":"Am J Physiol Hear Circ Physiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.yexcr.2008.08.015","article-title":"The role of neuregulin-1beta\/ErbB signaling in the heart.","volume":"315","author":"Pentassuglia","year":"2009","journal-title":"Exp Cell Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.110.991125","article-title":"Endothelium-derived neuregulin protects the heart against ischemic injury.","volume":"123","author":"Hedhli","year":"2011","journal-title":"Circulation."},{"key":"B119","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/cvr\/cvr352","article-title":"Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis.","volume":"93","author":"Hedhli","year":"2012","journal-title":"Cardiovasc Res."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006288","article-title":"Mechanisms of the multitasking endothelial protein NRG-1 as a compensatory factor during chronic heart failure.","volume":"12","author":"De Keulenaer","year":"2019","journal-title":"Circ Heart Fail."},{"key":"B121","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.hlc.2015.08.014","article-title":"Cardiac regeneration therapies \u2013 targeting neuregulin 1 signalling.","volume":"25","author":"Harvey","year":"2016","journal-title":"Hear Lung Circ."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1080\/15384101.2015.1063292","article-title":"The key roles of ERBB2 in cardiac regeneration.","volume":"14","author":"D\u2019Uva","year":"2015","journal-title":"Cell Cycle."},{"key":"B123","doi-asserted-by":"publisher","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","article-title":"Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes.","volume":"273","author":"Zhao","year":"1998","journal-title":"J Biol Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/ncb3149","article-title":"ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.","volume":"17","author":"D\u2019Uva","year":"2015","journal-title":"Nat Cell Biol."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5171","article-title":"Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window.","volume":"7","author":"Polizzotti","year":"2015","journal-title":"Sci Transl Med."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.05871","article-title":"Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish.","volume":"4","author":"Gemberling","year":"2015","journal-title":"Elife."},{"key":"B127","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060S0092-8674(09)00522-4","article-title":"Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury.","volume":"138","author":"Bersell","year":"2009","journal-title":"Cell."},{"key":"B128","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy.","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00395-005-0514-4","article-title":"Neuregulin receptors erbB2 and erbB4 in failing human myocardium \u2013 depressed expression and attenuated activation.","volume":"100","author":"Rohrbach","year":"2005","journal-title":"Basic Res Cardiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/01.cir.100.4.407","article-title":"Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors.","volume":"100","author":"Rohrbach","year":"1999","journal-title":"Circulation."},{"key":"B131","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/cvr\/cvv244","article-title":"Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension.","volume":"109","author":"Mendes-Ferreira","year":"2016","journal-title":"Cardiovasc Res."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137337","article-title":"RhNRG-1\u03b2 protects the myocardium against irradiation-induced damage via the ErbB2-ERK-SIRT1 signaling pathway.","volume":"10","author":"Gu","year":"2015","journal-title":"PLoS One."},{"key":"B133","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1054-3589(10)59002-1","article-title":"Neuregulin-1\/ErbB signaling and chronic heart failure.","volume":"59","author":"Xu","year":"2010","journal-title":"Adv Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2006.05.057","article-title":"Neuregulin-1\/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.","volume":"48","author":"Liu","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jacc.2009.12.044","article-title":"A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.","volume":"55","author":"Gao","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jacbts.2016.09.005","article-title":"A phase I, single ascending dose study of cimaglermin alfa (neuregulin 1\u03b23) in patients with systolic dysfunction and heart failure.","volume":"1","author":"Lenihan","year":"2016","journal-title":"JACC Basic to Transl Sci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.yjmcc.2011.06.016","article-title":"Neuregulin-1beta for the treatment of systolic heart failure.","volume":"51","author":"Sawyer","year":"2011","journal-title":"J Mol Cell Cardiol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.ejca.2007.06.024","article-title":"111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.","volume":"43","author":"de Korte","year":"2007","journal-title":"Eur J Cancer."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-06-3721","article-title":"Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.","volume":"67","author":"Gabrielson","year":"2007","journal-title":"Cancer Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/dot.2005.41.2.882662","article-title":"Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody.","volume":"41","author":"Harding","year":"2005","journal-title":"Drugs Today."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment.","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jjco\/hys005","article-title":"Japanese post-marketing surveillance of cetuximab (Erbitux\u00ae) in patients with metastatic colorectal cancer.","volume":"42","author":"Ishiguro","year":"2012","journal-title":"Jpn J Clin Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2310\/JIM.0b013e3182a6799d","article-title":"A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.","volume":"61","author":"Huang","year":"2013","journal-title":"J Investig Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin fab.","volume":"421","author":"Cho","year":"2003","journal-title":"Nature."},{"key":"B146","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell."},{"key":"B147","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors.","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer."},{"key":"B148","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.breast.2004.02.008","article-title":"Cardiac issues related to trastuzumab.","volume":"13","author":"Perez","year":"2004","journal-title":"Breast."},{"key":"B149","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical cardiac tolerability of trastuzumab.","volume":"22","author":"Perez","year":"2004","journal-title":"J Clin Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","article-title":"Trastuzumab-associated cardiotoxicity.","volume":"95","author":"Keefe","year":"2002","journal-title":"Cancer."},{"key":"B151","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4414\/smw.2007.11899","article-title":"The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.","volume":"137","author":"Yavas","year":"2007","journal-title":"Swiss Med Wkly."},{"key":"B152","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.821663","article-title":"The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment.","volume":"8","author":"Lin","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.","volume":"14","author":"Healey Bird","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/nejmra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice.","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.2009.26.0125","article-title":"Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?","volume":"28","author":"Morris","year":"2010","journal-title":"J Clin Oncol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1200\/JCO.2010.30.6274","article-title":"Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.","volume":"28","author":"Ewer","year":"2010","journal-title":"J Clin Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","article-title":"Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.","volume":"18","author":"Beauclair","year":"2007","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10549-013-2587-x","article-title":"Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.","volume":"139","author":"Roca","year":"2013","journal-title":"Breast Cancer Res Treat."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/annonc\/mdu111","article-title":"Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.","volume":"25","author":"Han","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/FPC.0000000000000149","article-title":"Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.","volume":"25","author":"G\u00f3mez Pe\u00f1a","year":"2015","journal-title":"Pharmacogenet Genomics."},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1298-6","article-title":"Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.","volume":"15","author":"Stanton","year":"2015","journal-title":"BMC Cancer."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93634-6","article-title":"Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer.","volume":"11","author":"Vazdar","year":"2021","journal-title":"Sci Rep."},{"key":"B165","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejm200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","article-title":"Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.","volume":"41","author":"Timolati","year":"2006","journal-title":"J Mol Cell Cardiol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mds328","article-title":"Pertuzumab: new hope for patients with HER2-positive breast cancer.","volume":"24","author":"Capelan","year":"2013","journal-title":"Ann Oncol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell."},{"key":"B170","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis.","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open."},{"key":"B172","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer."},{"key":"B174","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4065\/83.6.679","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial.","volume":"122","author":"Eiger","year":"2020","journal-title":"Br J Cancer."},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-015-0006-7","article-title":"Cardiac safety of afatinib: a review of data from clinical trials.","volume":"1","author":"Ewer","year":"2015","journal-title":"Cardio Oncol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","article-title":"Cardiotoxicity of novel HER2-targeted therapies.","volume":"29","author":"Sendur","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-08-1978","article-title":"A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.","volume":"15","author":"Wong","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/jjco\/hys012","article-title":"Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a phase 1 dose-escalation study.","volume":"42","author":"Ito","year":"2012","journal-title":"Jpn J Clin Oncol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience.","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology."},{"key":"B181","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib.","volume":"316","author":"Singh","year":"2020","journal-title":"Int J Cardiol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cbi.2016.08.006","article-title":"Progress on the cardiotoxicity of sunitinib: prognostic significance, mechanism and protective therapies.","volume":"257","author":"Yang","year":"2016","journal-title":"Chem Biol Interact."},{"key":"B183","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/jat.3584","article-title":"Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: past, present and future.","volume":"38","author":"Yang","year":"2018","journal-title":"J Appl Toxicol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1124\/mol.108.050104","article-title":"Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.","volume":"74","author":"Hasinoff","year":"2008","journal-title":"Mol Pharmacol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12012-009-9056-0","article-title":"Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.","volume":"10","author":"Hasinoff","year":"2010","journal-title":"Cardiovasc Toxicol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.taap.2010.08.026","article-title":"The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.","volume":"249","author":"Hasinoff","year":"2010","journal-title":"Toxicol Appl Pharmacol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ Res."},{"key":"B188","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/COC.0000000000000023","article-title":"Off-target effects of BCR-ABL and JAK2 inhibitors.","volume":"39","author":"Green","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase.","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci."},{"key":"B190","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","article-title":"Cardiac toxicity from systemic cancer therapy: a comprehensive review.","volume":"53","author":"Curigliano","year":"2010","journal-title":"Prog Cardiovasc Dis."},{"key":"B193","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur J Cancer."},{"key":"B194","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11906-011-0206-y","article-title":"Mechanisms of antiangiogenic-induced arterial hypertension.","volume":"13","author":"Mourad","year":"2011","journal-title":"Curr Hypertens Rep."},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci Transl Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med."},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010441","article-title":"Cancer therapy-induced cardiotoxicity-a metabolic perspective on pathogenesis, diagnosis and therapy.","volume":"23","author":"Choksey","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.630480","article-title":"Sunitinib and imatinib display differential cardiotoxicity in adult rat cardiac fibroblasts that involves a role for calcium\/calmodulin dependent protein kinase II.","volume":"7","author":"McMullen","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood."},{"key":"B200","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer."},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0036-7","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardio Oncol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer.","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.","volume":"61","author":"Sim\u016fnek","year":"2009","journal-title":"Pharmacol Rep."},{"key":"B205","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer."},{"key":"B206","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1124\/mol.64.3.670","article-title":"The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.","volume":"64","author":"Hasinoff","year":"2003","journal-title":"Mol Pharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijcard.2010.09.046","article-title":"Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.","volume":"154","author":"Cascales","year":"2012","journal-title":"Int J Cardiol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2015.12.021","article-title":"Cardioprotective effects of inorganic nitrate\/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane.","volume":"91","author":"Len\u00e8ov\u00e1-Popelov\u00e1","year":"2016","journal-title":"J Mol Cell Cardiol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/J.TOX.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology."},{"key":"B210","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.","volume":"18","author":"St\u00ecrba","year":"2013","journal-title":"Antioxid Redox Signal."},{"key":"B211","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/J.JACC.2019.04.067","article-title":"The evolution of \u03b2-blockers in coronary artery disease and heart failure (part 1\/5).","volume":"74","author":"Joseph","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"beta Blockade after myocardial infarction: systematic review and meta regression analysis.","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ."},{"key":"B213","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-associated cardiotoxicity.","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol Clin."},{"key":"B214","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail."},{"key":"B215","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity.","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J."},{"key":"B217","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am J Hematol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.","volume":"37","author":"Spallarossa","year":"2004","journal-title":"J Mol Cell Cardiol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","article-title":"Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.","volume":"185","author":"Santos","year":"2002","journal-title":"Toxicol Appl Pharmacol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/s0024-3205(99)00362-8","article-title":"Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.","volume":"65","author":"Matsui","year":"1999","journal-title":"Life Sci."},{"key":"B221","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy.","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial.","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology."},{"key":"B223","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity.","volume":"69","author":"Nabati","year":"2017","journal-title":"J Cardiovasc Pharmacol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.","volume":"18","author":"El-Shitany","year":"2012","journal-title":"J Card Fail."},{"key":"B226","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/J.JACC.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer.","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-015-0435-5","article-title":"Review of nebivolol pharmacology and clinical evidence.","volume":"75","author":"Fongemie","year":"2015","journal-title":"Drugs."},{"key":"B228","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.","volume":"44","author":"de Nigris","year":"2008","journal-title":"Eur J Cancer."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.5114\/aoms.2018.79008","article-title":"Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats.","volume":"14","author":"Mohamed","year":"2018","journal-title":"Arch Med Sci."},{"key":"B230","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/CMAR.S166481","article-title":"Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer.","volume":"10","author":"Cochera","year":"2018","journal-title":"Cancer Manag Res."},{"key":"B232","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-020-00090-0","article-title":"The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity.","volume":"72","author":"Ayuna","year":"2020","journal-title":"Egypt Hear J."},{"key":"B234","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/hr.2009.184","article-title":"Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.","volume":"33","author":"Hanif","year":"2010","journal-title":"Hypertens Res."},{"key":"B235","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jat.782","article-title":"Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats.","volume":"21","author":"Abd El-Aziz","year":"2001","journal-title":"J Appl Toxicol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1385\/ct:3:4:319","article-title":"Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity.","volume":"3","author":"Boucek","year":"2003","journal-title":"Cardiovasc Toxicol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cvr\/cvx162","article-title":"Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.","volume":"114","author":"Hullin","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B238","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1254\/jjp.88.183","article-title":"Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters.","volume":"88","author":"Okumura","year":"2002","journal-title":"Jpn J Pharmacol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","article-title":"Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.","volume":"22","author":"Silber","year":"2004","journal-title":"J Clin Oncol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijcard.2005.08.061","article-title":"Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats.","volume":"110","author":"Soga","year":"2006","journal-title":"Int J Cardiol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","article-title":"Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.","volume":"160","author":"Cadeddu","year":"2010","journal-title":"Am Heart J."},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-198","article-title":"Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on epirubin-induced inflammation and oxidative stress assessed by serial strain rate.","volume":"2","author":"Dess\u00ec","year":"2013","journal-title":"Springerplus."},{"key":"B245","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3892\/etm.2011.305","article-title":"Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction.","volume":"2","author":"Dess\u00ec","year":"2011","journal-title":"Exp Ther Med."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial.","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"B250","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J."},{"key":"B251","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy.","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"B252","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4070\/kcj.2017.0030","article-title":"Current drug therapy in chronic heart failure: the new guidelines of the european society of cardiology (ESC).","volume":"47","author":"Berliner","year":"2017","journal-title":"Korean Circ J."},{"key":"B253","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B254","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J."},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.683281","article-title":"Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.","volume":"8","author":"Pan","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B256","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12012-021-09665-y","article-title":"Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways.","volume":"21","author":"Bar\u0131\u015f","year":"2021","journal-title":"Cardiovasc Toxicol."},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction.","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure.","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J."},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-Glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy.","volume":"12","author":"Ren","year":"2021","journal-title":"Front Pharmacol."},{"key":"B261","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2013.11.001","article-title":"Ranolazine in the prevention of anthracycline cardiotoxicity.","volume":"79","author":"Corradi","year":"2014","journal-title":"Pharmacol Res."},{"key":"B262","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1111\/bph.13791","article-title":"Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.","volume":"174","author":"Cappetta","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/01.res.76.4.645","article-title":"Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium.","volume":"76","author":"Wang","year":"1995","journal-title":"Circ Res."},{"key":"B264","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00038","article-title":"Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production.","volume":"9","author":"Riccio","year":"2018","journal-title":"Front Physiol."},{"key":"B266","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1124\/jpet.119.258178","article-title":"Pharmacology of ranolazine versus common cardiovascular drugs in patients with early diastolic dysfunction induced by anthracyclines or nonanthracycline chemotherapeutics: a phase 2b minitrial.","volume":"370","author":"Minotti","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation."},{"key":"B268","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.","volume":"334","author":"Koka","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B269","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jjcc.2013.03.018","article-title":"Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.","volume":"62","author":"Jin","year":"2013","journal-title":"J Cardiol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"12944","DOI":"10.1074\/JBC.M404706200","article-title":"Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.","volume":"280","author":"Das","year":"2005","journal-title":"J Biol Chem."},{"key":"B271","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.118.036652","article-title":"Short-chain fatty acid propionate protects from hypertensive cardiovascular damage.","volume":"139","author":"Bartolomaeus","year":"2019","journal-title":"Circulation."},{"key":"B272","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1042\/CS20200128","article-title":"Short-chain fatty acid, acylation and cardiovascular diseases.","volume":"134","author":"Chen","year":"2020","journal-title":"Clin Sci (Lond)."},{"key":"B273","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ejhf.1439","article-title":"The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.","volume":"21","author":"Russo","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020729","article-title":"Ketone ester D-\u03b2-hydroxybutyrate-(R)-1,3 butanediol prevents decline in cardiac function in type 2 diabetic mice.","volume":"10","author":"Thai","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B275","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/JIR.S331320","article-title":"\u03b2-hydroxybutyrate mitigated heart failure with preserved ejection fraction by increasing treg cells via Nox2\/GSK-3\u03b2.","volume":"14","author":"Liao","year":"2021","journal-title":"J Inflamm Res."},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603596","article-title":"Cardioprotective roles of \u03b2-hydroxybutyrate against doxorubicin induced cardiotoxicity.","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system.","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res."},{"key":"B278","doi-asserted-by":"publisher","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins.","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation."},{"key":"B279","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/J.JACC.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B280","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B281","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cjca.2014.11.020","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can J Cardiol."},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score\u2014matched cohort study.","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B283","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","article-title":"Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy.","volume":"35","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"Can J Cardiol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.yjmcc.2003.09.012","article-title":"Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase\/Akt.","volume":"35","author":"Fukazawa","year":"2003","journal-title":"J Mol Cell Cardiol."},{"key":"B285","doi-asserted-by":"publisher","first-page":"H1974","DOI":"10.1152\/ajpheart.01010.2008","article-title":"Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.","volume":"297","author":"Bian","year":"2009","journal-title":"AJP Hear Circ Physiol."},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v6.i7.653","article-title":"Neuregulin-1\/erbB activities with focus on the susceptibility of the heart to anthracyclines.","volume":"6","author":"Vasti","year":"2014","journal-title":"World J Cardiol."},{"key":"B287","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.113.002203","article-title":"An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.","volume":"128","author":"Jay","year":"2013","journal-title":"Circulation."},{"key":"B288","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/S0083-6729(01)63006-1","article-title":"Granulocyte colony-stimulating factor and its receptor.","volume":"78","author":"Demetri","year":"1991","journal-title":"Blood."},{"key":"B289","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/labinvest.3700530","article-title":"Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy.","volume":"87","author":"Li","year":"2007","journal-title":"Lab Invest."},{"key":"B290","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/eurheartj\/ehl044","article-title":"Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.","volume":"27","author":"Hamed","year":"2006","journal-title":"Eur Heart J."},{"key":"B291","first-page":"57","article-title":"The potential health benefits of taurine in cardiovascular disease.","volume":"13","author":"Xu","year":"2008","journal-title":"Exp Clin Cardiol."},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-80984-4","article-title":"Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS\/EPC pathway.","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep."},{"key":"B293","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/cvr\/cvaa181","article-title":"Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity.","volume":"117","author":"Gal\u00e1n-Arriola","year":"2021","journal-title":"Cardiovasc Res."},{"key":"B294","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2015.05.026","article-title":"Dynamics of cell generation and turnover in the human heart.","volume":"161","author":"Bergmann","year":"2015","journal-title":"Cell."},{"key":"B295","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1164680","article-title":"Evidence for cardiomyocyte renewal in humans.","volume":"324","author":"Bergmann","year":"2009","journal-title":"Science."},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.750604","article-title":"Reawakening the intrinsic cardiac regenerative potential: molecular strategies to boost dedifferentiation and proliferation of endogenous cardiomyocytes.","volume":"8","author":"Bongiovanni","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B297","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European society of cardiology.","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.847012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T02:06:55Z","timestamp":1649988415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.847012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":297,"alternative-id":["10.3389\/fcvm.2022.847012"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.847012","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"article-number":"847012"}}